No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LUMO Lumos Pharma
- 2.810
- +0.015+0.54%
Trading Apr 25 14:23 ET
22.81MMarket Cap-672P/E (TTM)
2.810High2.713Low1.19KVolume2.760Open2.795Pre Close3.26KTurnover0.02%Turnover RatioLossP/E (Static)8.12MShares4.55052wk High0.84P/B14.93MFloat Cap2.41052wk Low--Dividend TTM5.31MShs Float36.720Historical High--Div YieldTTM3.46%Amplitude2.410Historical Low2.736Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Lumos Pharma Announces Abstracts Reviewing Data From Its Phase 2 OraGrowth210 And OraGrowth212 Trials Will Be Presented At Upcoming Medical Meetings
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes
Express News | Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
Comments
Let’s see what good stuff comes from these?
$Lumos Pharma(LUMO.US$ Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...
AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...
News
$Lumos Pharma(LUMO.US$ Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
1
Update
$Lumos Pharma(LUMO.US$ © Reuters. Lumos Pharma (ticker: NASDAQ:LUMO) has announced promising top-line results from its OraGrowtH210 and OraGrowtH212 trials for LUM-201, highlighting its potential as an oral treatment for pediatric growth hormone deficiency (PGHD). The company detailed plans for future trials and regulatory discussions during its recent earnings call. With $36.1 million in cash at the end of 2023, Lumos Pharma is funded through Q3 2024 and is actively exploring partnership...
Seminar Started
$Lumos Pharma(LUMO.US$
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
1
Today's trading is a short-seller's fiesta, but long players aren't left in the dust either!
Today's trading is a short-seller's fiesta, but long players aren't left in the dust either!
✅ CDIO bucked the trend with a strategic 13.04% LONG MOVE and nimbly dipped 13.99% on the short side!
💥 HSCS is the short sensation, dropping a massive 57.85%!
💣 BIOL, LUMO, and BYU are making waves with short moves of 18.99%, 18.66%, and a whopping 27.34%, respectively!
See you all tomorrow AM for another rou...
✅ CDIO bucked the trend with a strategic 13.04% LONG MOVE and nimbly dipped 13.99% on the short side!
💥 HSCS is the short sensation, dropping a massive 57.85%!
💣 BIOL, LUMO, and BYU are making waves with short moves of 18.99%, 18.66%, and a whopping 27.34%, respectively!
See you all tomorrow AM for another rou...
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg